The document provides information on cervical cancer including:
1. Statistics on global cancer incidence and mortality with cervical cancer among the most common cancers.
2. Risk factors for cervical cancer including human papillomavirus infection, young age of first intercourse, multiple sexual partners, and smoking.
3. Screening guidelines recommend co-testing with cytology and HPV testing every 5 years for women aged 30-65 or cytology alone every 3 years.
Management of Early Stage Carcinoma CervixSubhash Thakur
This presentation covers the management of early stage carcinoma cervix (FIGO stage I to IIA). A brief introuduction to different surgical procedures and the radiation treatment techninques have been described.
Management of cacrinoma cervix: Techniques of radiotherapy (2D conventional, 3D Conformal radiotherapy (3DCRT) and IMRT with a review of various contouring guidelines.
The combined use of radiation therapy and chemotherapy in cancer treatment is a logical and reasonable approach that has already proven beneficial for several malignancies.
This is a concise presentation on the pathology of endometrial cancer based on the latest WHO female genital tumors latest edition, 5th edition
prepared on April 2022
Management of Early Stage Carcinoma CervixSubhash Thakur
This presentation covers the management of early stage carcinoma cervix (FIGO stage I to IIA). A brief introuduction to different surgical procedures and the radiation treatment techninques have been described.
Management of cacrinoma cervix: Techniques of radiotherapy (2D conventional, 3D Conformal radiotherapy (3DCRT) and IMRT with a review of various contouring guidelines.
The combined use of radiation therapy and chemotherapy in cancer treatment is a logical and reasonable approach that has already proven beneficial for several malignancies.
This is a concise presentation on the pathology of endometrial cancer based on the latest WHO female genital tumors latest edition, 5th edition
prepared on April 2022
Gall bladder carcinoma seen in Indian popluation most common in women and presents at a very late stage .Survival is in months hence palliative treatment is being preferred .
CCSN welcomed back Helene Hutchings to discuss anal and colorectal cancer in this educational webinar. Helene discussed the symptoms & risk factors of these cancers, as well as treatment options that are available.
She also discussed prevention of anal and colorectal cancers and the benefits of peer-to-peer support groups.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Understanding colorectal and anal cancer, including symptoms, risk factors
● Treatment options, including chemotherapy, radiation and biologics
● Preventing colorectal and anal cancer
View the video: https://youtu.be/q0z8N1_L-JQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
4. Statistics
• >9.7 million cases are detected each
year
• 6.7 million people will die from
cancer
• Every day, around 1700 Americans
die of the disease
• 20.4 million people living with
cancer in the world today
• 1 in 3 people will be diagnosed with
cancer in the UK and 1 in 4 will die
from their disease
11. 6/1/2018 3:44:47 AM 11
Causes and risk factor
Coitus at young age: <16 years old increased risk by 50%
Number of sexual partners: 6 sexual partners or more increase risk
by 14.2 folds.
Smoking- Smoking for> 12 years increase the risk by 12.7 folds.
Male related risk factors:
Number of the partners previous sexual relationships is relevant .
cervical cancer risk increased if partners has penile cancer
(circumcision)
Previous wife with cervical cancer.
Previous CIN
Long term use of the contraceptive pill increase the risk due to
increasing exposure to seminal fluids.
Immuno suppresion risk increased with immuno suppressed renal
transplant patients and in HIV positive women.
HPV (Human papilloma virus ) infection mainly 16,18
the main aetiological is infection with subtypes of HPV (16,18)
Low socioecomic class
12. HPV 16,18
Smoking Cervical cell Male factors
Infhibation of CX
cellp53 tumour
suppression gyne
Protection against
tumour
development lifted
Cancer develops
13. Type of patient:
• Multiparous.
• Low socioeconomic class.
• Poor hygiene.
• Prostitutes.
• Low incidence in Muslims and Jews.
14. Predisposing factors:
• Cervical dysplasia.
• (Cervical intraepithelial neoplasia)
• CIN III / CARCINOMA IN SITU
• THE LESION PROCEEDS THE INVASION BY 10-
12 YEARS
15.
16.
17.
18.
19. Pathology type
• Squamous cell carcinoma- 90%.
• Adenocarcinoma- 10%.
• TYPES OF GROWTH
• Exophytic: is like cauliflower filling up the
vaginal vualt.
• Endophytic: it appears as hard mass with a
good deal of induration.
• Ulcerative: an ulcer in the cervix.
20. SPREAD:
Direct Lymphatic Dissemination
(late)
- Uteruq.
- Vagina.
- Parametrium.
- Bladder and rectum.
A- primary node:
parametrial.
Paracervical.
Vesicovaginal.
Rectovaginal.
Hypogastric.
Obturator and external iliac
B-Secondary nodes:
Common iliac
Sacral
Vaginal
Paraaortic
Inguinal.
- parametrial spread
causes obstruction of the
ureters, many deaths occur
due to uraemia.
- Obstruction to the
cervical canal results in
pyometria.
21. Symptoms:
Early symptoms Late symptoms
- None.
- Thin, watery, blood tinged
vaginal discharge frequently
goes unrecognized by the
patient.
- Abnormal vaginal bleeding
Intermenstrual
Postcoital
Perimenopausal
Postmenopausal
- Blood stained foul vaginal
discharge.
- Pain, leg oedema.
- Urinary and rectal
symptoms
dysuria
haematuria
rectal bleeding
constipation
haemorrhoids
- Uraemia
22. DIAGNOSIS
1- History.
• Many women are a symptomatic .
• Presented with abnormal routine cx smear
• Complain of abnormal vaginal bleeding
• I M bleeding
• post coital bleeding
• perimenopausal bleeding
• postmenopausal bleeding
• blood stain vaginal discharge
23. 2- Examination:
• Mainly vaginal examination using cuscu’s
speculem nothing is found in early stage .
• Mass ,ulcerating fungating in the cervix
• P/V P/R is very helful.
26. Preoperative evaluation
• Review her history.
• General examination:
o Anaemia.
o Lymphadenopathy-Supraclavicular LN.
o Renal area.
o Liver or any palpable mass.
o Oedema.
• Laboratory tests:
o CBC, LFT, RFT, Urine analysis.
o Tumour markers.
o Chest X- ray, abdominal X- ray, IVU.
o CAT, MRI, if necessary.
o Ultrasound.
o Lymphography, if necessary.
27. Staging
Best to follow FIGO system.
• Examination under anaesthesia.
• Bimanual palpation.
• P/V, P/R.
• Cervical biopsy, uterine biopsy.
• Cystoscopy, Proctoscopy, if necessary.
28. SPREAD:
Direct Lymphatic Dissemination
(late)
- Uteruq.
- Vagina.
- Parametrium.
- Bladder and rectum.
A- primary node:
parametrial.
Paracervical.
Vesicovaginal.
Rectovaginal.
Hypogastric.
Obturator and external iliac
B-Secondary nodes:
Common iliac
Sacral
Vaginal
Paraaortic
Inguinal.
- parametrial spread
causes obstruction of the
ureters, many deaths occur
due to uraemia.
- Obstruction to the
cervical canal results in
pyometria.
31. The choice of treatment will depend on
• Fitness of the patients
• Age of the patients
• Stage of disease.
• Type of lesion
• Experience and the resources avalible.
34. Werthemeim’s hystrectomy
• Total abdominal hystrectomy including the
parametrium.
• Pelvic lymphadenectomy
• 3 cm vaginal cuff
• The original operation conserved the ovaries
,since squamouss cell carcinoma does not
spread dirctly to the ovaries.
• Oophorectomy should be performed in cases
of adenocarcinoma as there is 5-10% of
ovarian metastosis
35. Surgery offers several advantage
• It allows presentation of the ovaries (radiotherapy will
destroythem).
• There is better chance of preserving sexual function.
• (vaginal stonosis occur in up 85% of irradiates.
• Psychological feeling of removing the disease from the
body .
• More accute staging and prognsis
• Glandular tumours (adenocarcinomas) are not
detectable by screening are associated with skip
lesions and require radical surgery.
•
36. COMPLICATIONS OF SURGERY
• Haemorrhage: primary or secondary.
• Injury to the bladder, uerters.
• Bladder dysfunction.
• Fistula.
• Lymphocele.
• Shortening of the vagina.
43. -PelvicExenteration
- Neoadjuvant chemotherapy or concurrent chemoradiotherapy
- Palliative Radiotherapy
• Surgical Exenteration : Selected patients of stage IV, with no or minimal parametrial invasion
may be treated with primary exenterative surgery, the extent of which (anterior, posterior or
total) would depend on the extent of the lesion.
• Neoadjuvant chemotherapy or concurrent chemoradiotherapy
Selected patients with good general and renal status and not suitable for surgical
exenteration can be treated with this approach with radical intent.
• Palliative Radiotherapy: The majority of stage IVA patients has poor general condition and
extensive local disease in our setting and are best treated with palliative radiation therapy
alone. A short palliative regime of 30 Gy in 10 fractions over two weeks or 30 Gy / 3# / 60
days (10 Gy / every month x 3#) is generally used and in few patients who respond very well,
this is followed by intracavitary application.
Stage IVA :
6/1/2018 3:44:47 AM 43
44. • Very bulky disease
• With paraaortic node
• Satge IV A disease[bladder and rectum inv.]
•2cycle NACT
•f/b radiation
Neoadjuvant chemotherapy or
concurrent chemoradiotherapy
6/1/2018 3:44:47 AM 44
46. PROGNOSIS
Depends on:
• Age of the patient.
• Fitness of the patient.
• Stage of the disease.
• Type of the tumour.
• Adequacy of treatment.
47. THE OVERALL 5 YEARS SURVIVAL FOLLOWING
THERAPY:
• Stage I -------80%
• Stage II-------50-60%
• Stage III-------30-40%
• Stage IV-------4%
48. • I. clinical Examination
– 3monthly for first 2year
– 6monthly for after 2year
– Annually there after
• II. No other investigations in asymptomatic
patients for early detection of metastasis, since it
is -
– Not cost-effective
– Does not prolong survival.
– Detection and disclosure of spread of disease may be
psychologically harmful to an asymptomatic
6/1/2018 3:44:47 AM 48
Follow-up
49. Vaginal dilator
• On completion of
treatment all
patients are given a
vaginal dilator to use
until vaginal mucosa
healed, this prevents
vaginal stenosis.
• Premenopausal
patients commenced
on HRT:
6/1/2018 3:44:47 AM 49
50. 6/1/2018 3:44:47 AM 50
With in 3 month follow up
1. No pap smear/bx
2. Confusion about radiation changes
3. Unnecessary investigation
4. Anxiety
5. Unnecessary treatment
51. Criteria Grade Recommendation
Cytology only, 21 to 65 years old A Every 3 years
Cytology + HPV co-testing, 30-65 years old A Every 5 years
Women under 21 years old D Avoid screening
Age ≥ 65 with adequate prior screening and
not high risk
D Avoid screening
Total hysterectomy; benign disease D Avoid screening
HPV testing, alone or in combination, < 30
years old
D Avoid screening
USPSTF Cervical Cytology Guidelines
March 2012
52. Age Screening
< 21 No Screening
21-29 Cytology alone every 3 years
30-65 Preferred: Cytology + HPV every 5 years* OR
Acceptable: Cytology alone every 3 years*
> 65 No screening, following adequate neg prior screens
After total hysterectomy No screening, if no history of CIN2+ in the past 20
years of cervical cancer ever
Triple A Guideline: ACS, ASCCP,
American Society for Clinical Pathology
CA Cancer J CLIN March 2012
*If cytology result is negative or ASCUS + HPV negative
53. Summary of Important Guideline Changes
• 1st time that all 3 organizations involved with cervical cancer
prevention and the USPSTF have endorsed equivalent
guidelines
• Co-testing is “ready for primetime” for women ≥ 30
-But, co-testing every 5 years (NOT every 3 years)
• Women 21-29: cytology every 3 years (NOT 1 or 2)
• Stop screening women under 21 years of age
• Stop screening women 65 and older if negative results and
adequate prior screening
54. • There are two HPV vaccines (Gardasil and Cervarix) which
reduce the risk of cancerous or precancerous changes of the
cervix and perineum by about 93%.
• HPV vaccines are typically given to women age 13 to 26 as the
vaccine is only effective if given before infection occurs.
• The vaccines have been shown to be effective for at least 4 to
6 years, and it is believed they will be effective for longer;
however, the duration of effectiveness and whether a booster
will be needed is unknown
6/1/2018 3:44:47 AM 54
Vaccination strategy
55. Delivered 5 days per week over 6-8 weeks
Typical treatment takes around 5 minutes
Treatment is painless--like having an X-ray taken
No radioactive substances involved; beam goes
on/off
Side effects usually temporary; controlled with
medication/diet
Covered by Medicare and many other insurance
companies
6/1/2018 3:44:47 AM 55
Treatment
60. GOALS
High dose to tumor tissue-Tumor control
Normal tissue sparing
Minimize long and short term toxicities
Better Quality of life
6/1/2018 3:44:47 AM 60
61. 6/1/2018 3:44:47 AM 61
Evolution of Treatment Techniques
CONVENTIONAL RT
Collimator shapes Beam
Rectangular Treatment Field
Shaped Treatment Field
1970s and earlier
63. IMRT
• Divides each treatment field into
multiple segments
• Modulates beam intensity,
giving discrete dose to each
segment
• Uses multiple, shaped beams
(~9) and thousands of segments
IMRT Initiated in 1995
Reached the clinic in 2000
72. 6/1/2018 3:44:47 AM 73
Ref image
First EPID
2 nd EPID
OK
Set-up verification
Using EPID
73.
74. • Short distance /contact with tumor
• Expertise needed
• Invasive procedure
• Adequetly sparing normal structure
• Well established
6/1/2018 3:44:47 AM 76
Brachytherapy
107. CAUTION
C - Change in bowel or bladder habits
A - A sore that does not heal
U - Unusual bleeding or discharge
T - Thickening or lump in the breast or any part of the body
I - Indigestion or difficulty swallowing
O - Obvious change in a wart or mole
N - Nagging cough or hoarseness
141. TEAM OF EXPERTS IN SURGICAL ONCOLOGY
1. Dr.Murali Krishna Voonna M.S.,M.Ch.,
(Adyar Cancer Institute ,Chennai)
2. Dr.Karthik Chandra Vallam M.S., M.Ch,DNB.,
(TATA Memorial ,Mumbai)
3. Dr.M.P.S.Chandra Kalyan M.S,, M.Ch.,
(TATA Memorial ,Mumbai)
142. TEAM OF EXPERTS IN RADIATION ONCOLOGY
Dr. Kanhu Charan Patro M.D(RT).DNB(RT)
(ex. TATA Memorial ,Mumbai)
Dr. Partha Sarathi Bhattacharyya M.D (RT)
(ex. AIIMS,NEW DELHI)
Dr. Chittaranjan Kundhu M.D(RT)
(S.C.B.M.C ,Cuttack)
Dr. Venkata Krishna Reddy M.D (RT)
(ex.Christian Medical College ,Vellore)
143. TEAM OF EXPERTS IN MEDICAL ONCOLOGY
1. Dr. B.Rakesh Reddy M.D(Paed).,DM
(Medical Oncology) (AIIMS ,New Delhi)
2. Dr. M.Vamshi Krishna M.D.,D.M., (Medical Oncology)
(Tata Memorial ,Mumbai)
3. Dr.R.Madhan Mohan M.D. (Hematology)
(AIIMS ,New Delhi)
144. TEAM OF EXPERTS IN CRITICAL CARE AND PAIN
1. Dr. K.V.D. Praveen M.D(Anesthesiology)
(PGIMER, Chandigarh)
2. Dr. A.Shirisha M.D (Anesthesiology)
(AMC ,Visakhapatnam)
3. Dr. Surendra Nadh D.A, DNB(Anesthesiology)
(ISPAT General Hospital, Odisha)
145. TEAM OF EXPERTS-- Radiology
1. Dr. P.Madhuri D.M.R.D
( AMC ,Visakhapatnam)
2. Dr. B.Revathi D.M.R.D
( RMC ,Kakinada)
148. EXPERTS FROM VARIOUS PRESTIGIOUS
INSTITUTIONS
1. ADYAR CANCER INSTITUTE, CHENNAI-1
2. TATA MEMORIAL HOSPITAL, MUMBAI-3
3. AIIMS,NEWDELHI-2
4. CMC-VELLORE-1
5. PGI-CHANDIGARH-2